Avalo Therapeutics, Inc. (AVTX)

11,49 -0,24 (-2,05%) Alla chiusura: 04:00PM EDT

Avalo Therapeutics, Inc.

540 Gaither Road
Suite 400
Rockville, MD 20850
United States
410-522-8707
https://www.avalotx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 19

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Garry A. Neil M.D.	Chairman of the Board, President & CEO	475k	N/D	1954
Mr. Christopher Ryan Sullivan	CFO & Head of Investor relations	350k	N/D	1984
Dr. Solomon H. Snyder M.D.	Founder and Chairman of Scientific Advisory Board	N/D	N/D	1939
Dr. Barbara S. Slusher Ph.D.	Founder and Member of Scientific Advisory Board	N/D	N/D	1965
Dr. Lisa Hegg Ph.D.	Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations	N/D	N/D	N/D
Ms. Colleen Matkowski	Senior Vice President of Global Regulatory Affairs & Quality Assurance	N/D	N/D	N/D
Dr. Dino C. Miano Ph.D.	Senior Vice President of CMC & Technical Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Governance aziendale

L'ISS Governance QualityScore di Avalo Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.